{"entity":{"id":"paper-eln-2022-aml-dohner-blood-2022","kind":"paper","name":"ELN 2022: diagnosis and management of acute myeloid leukaemia in adults","aka":[],"tldr":"The European LeukemiaNet 2022 recommendations define how acute myeloid leukaemia is classified by its genetics into favourable, intermediate and adverse risk, and how those groups should be treated and monitored.","summary":"International expert panel recommendations updating the 2017 European LeukemiaNet guidance on AML diagnosis, genetic risk classification, response criteria, measurable residual disease and treatment, aligned with the 2022 WHO and International Consensus classifications.\n\nKey changes include FLT3-ITD moving to intermediate risk regardless of allelic ratio, the addition of adverse-risk myelodysplasia-related gene mutations, and new criteria for measurable residual disease assessment.","asOf":"2026-09-17","links":[{"label":"Blood 2022","url":"https://doi.org/10.1182/blood.2022016867"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/35797463/"}],"tags":[],"related":[],"cancers":["aml-older-unfit","aml-flt3","aml-npm1-kmt2a","aml-idh","aml-secondary"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["blood"],"dependsOn":[],"notes":[],"journal":"Blood","year":2022,"doi":"10.1182/blood.2022016867","pmid":"35797463","authors":"Döhner H, Wei AH, Appelbaum FR, et al.","paperType":"guideline","findings":[],"whatItMeans":"The risk category on an AML report, and therefore whether a patient is steered towards transplant in first remission, comes from these recommendations.","caveats":["Risk categories were derived largely from intensively treated patients and predict less well under venetoclax-based regimens."],"changedPractice":true},"route":"/key-papers/paper-eln-2022-aml-dohner-blood-2022/","neighbours":{"cancer":[{"id":"aml-older-unfit","kind":"cancer","name":"Acute myeloid leukaemia in older or unfit patients","route":"/cancers/aml-older-unfit/"},{"id":"aml-flt3","kind":"cancer","name":"FLT3-mutated acute myeloid leukaemia","route":"/cancers/aml-flt3/"},{"id":"aml-idh","kind":"cancer","name":"IDH1- and IDH2-mutated acute myeloid leukaemia","route":"/cancers/aml-idh/"},{"id":"aml-npm1-kmt2a","kind":"cancer","name":"NPM1-mutated and KMT2A-rearranged acute myeloid leukaemia","route":"/cancers/aml-npm1-kmt2a/"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/"}],"journal":[{"id":"blood","kind":"journal","name":"Blood","route":"/journals/blood/"}]}}